| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.046 | 0.1 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.051 | 0.1 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.075 | 0.1 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.1 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.1 |